HHealthcare Read More Eli Lilly’s Orforglipron Data Is Not Disastrous: Analyst – Eli Lilly (NYSE:LLY)August 12, 2025 Eli Lilly and Co LLY released underwhelming data from a Phase 3 ATTAIN-1 trial evaluating orforglipron, an investigational…